TPEX:4188

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

NT$934.0m

Last Updated

2021/06/22 08:41 UTC

Data Sources

Company Financials

Executive Summary

AmCad BioMed Corporation develops computer-assisted detection and diagnosis (CAD) software devices primarily in Taiwan. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has AmCad BioMed's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4188 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: 4188's weekly volatility (2%) has been stable over the past year.


Market Performance


7 Day Return

0.3%

4188

5.6%

TW Medical Equipment

-1.3%

TW Market


1 Year Return

-40.1%

4188

-2.2%

TW Medical Equipment

45.3%

TW Market

Return vs Industry: 4188 underperformed the TW Medical Equipment industry which returned -2.2% over the past year.

Return vs Market: 4188 underperformed the TW Market which returned 45.3% over the past year.


Shareholder returns

4188IndustryMarket
7 Day0.3%5.6%-1.3%
30 Day-4.1%12.5%5.2%
90 Day-9.5%16.0%6.3%
1 Year-40.1%-40.1%-0.03%-2.2%49.9%45.3%
3 Year-46.3%-46.3%22.4%12.0%74.8%55.6%
5 Year-48.7%-48.7%11.6%-3.1%138.4%97.3%

Long-Term Price Volatility Vs. Market

How volatile is AmCad BioMed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AmCad BioMed undervalued compared to its fair value and its price relative to the market?

1.88x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4188's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4188's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4188 is unprofitable, so we can't compare its PE Ratio to the TW Medical Equipment industry average.

PE vs Market: 4188 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4188's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4188 is good value based on its PB Ratio (1.9x) compared to the TW Medical Equipment industry average (2.1x).


Future Growth

How is AmCad BioMed forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AmCad BioMed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has AmCad BioMed performed over the past 5 years?

8.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4188 is currently unprofitable.

Growing Profit Margin: 4188 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4188 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.6% per year.

Accelerating Growth: Unable to compare 4188's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4188 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.9%).


Return on Equity

High ROE: 4188 has a negative Return on Equity (-6.42%), as it is currently unprofitable.


Financial Health

How is AmCad BioMed's financial position?


Financial Position Analysis

Short Term Liabilities: 4188's short term assets (NT$418.7M) exceed its short term liabilities (NT$46.3M).

Long Term Liabilities: 4188's short term assets (NT$418.7M) exceed its long term liabilities (NT$21.6M).


Debt to Equity History and Analysis

Debt Level: 4188 is debt free.

Reducing Debt: 4188 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4188 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4188 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 14.3% each year


Dividend

What is AmCad BioMed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4188's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4188's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4188's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4188's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4188's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Yi-Li Lee

3.17yrs

Tenure

Ms. Yi-Li Lee serves as President of Amcad Biomed Corp. since April 20, 2018 and serves as Deputy Chairperson since November 6, 2020.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AmCad BioMed Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AmCad BioMed Corporation
  • Ticker: 4188
  • Exchange: TPEX
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: NT$934.036m
  • Shares outstanding: 53.22m
  • Website: https://amcad.com.tw

Number of Employees


Location

  • AmCad BioMed Corporation
  • No. 167 Fuxing North Road
  • 3rd Floor
  • Taipei
  • 104
  • Taiwan

Listings


Biography

AmCad BioMed Corporation develops computer-assisted detection and diagnosis (CAD) software devices primarily in Taiwan. Its products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroi...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/22 08:41
End of Day Share Price2021/06/21 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.